Curevac N.V. ((CVAC)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: CureVac N.V. is conducting a Phase I study titled Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC). The study aims to evaluate the safety and tolerability of the CVHNLC mRNA vaccine in combination with pembrolizumab, targeting metastatic squamous non-small-cell lung cancer. This research is significant as it explores innovative mRNA technology in cancer treatment.
Intervention/Treatment: The study tests the CV09070101 mRNA vaccine (CVHNLC) at various dose levels, combined with pembrolizumab, and later with chemotherapy agents carboplatin and paclitaxel. The goal is to find a safe and effective dose for treating sqNSCLC.
Study Design: This is an open-label, non-randomized, sequential intervention study. It focuses on treatment, with no masking involved, to assess the vaccine’s safety and tolerability in a real-world setting.
Study Timeline: The study was first submitted on July 9, 2025, with the same date marking its last update. It is currently not yet recruiting, indicating that patient enrollment has not started.
Market Implications: This study could impact CureVac’s stock performance positively if successful, as it represents a potential breakthrough in mRNA cancer therapies. Investors may watch closely, considering the competitive landscape with other companies exploring similar technologies.
The study is ongoing, and further details are available on the ClinicalTrials portal.